Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS)

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 751-757

  Fagerholm, Urban ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATOVAQUONE; DANAZOL; ENALAPRILAT; GRISEOFULVIN; LEVOSIMENDAN; METOPROLOL; NAPROXEN; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

BIOEQUIVALENCE; COMPUTER MODEL; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFORMATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; REVIEW;

EID: 34447329572     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.6.0001     Document Type: Review

References (44)

1. Adkin, D. A., Davis, S. S., Sparrow, R. A., Huckle, P. D., Phillips, A. J., Wilding, I. R. (1995) The effects of pharmaceutical excipients on small intestinal transit. Br. J. Clin. Pharmacol. 39: 381-387
2. Amidon, G. L., Lennernäs, H., Shah, V., Crison, J. (1995) A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12: 413-420
3. Artursson, P., Karlsson, J. (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochim. Biophys. Res. Commun. 175: 880-885
4. Artursson, P., Palm, K., Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Del. Rev. 46: 27-43
5. Barends, D. M. (2005) Application and experience in the EU of BCS in the review of new generics. J. Pharm. Pharmacol. 57 (Suppl.): 117
6. Bergstrom, C. A. (2005) In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin. Pharmacol. Toxicol. 96: 156-161
7. Bønløkke, L., Hovgaard, L., Kristensen, H. G., Knutson, L., Lennernäs, H. (2001) Direct estimation of the in vivo dissolution, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut®) in humans. Eur. J. Pharm. Sci. 12: 239-250
8. Clark, D. E. (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. prediction of intestinal absorption. J. Pharm. Sci. 88: 807-814
9. Clark, D. E., Grootenhuis, P. D. J. (2003) Predicting passive transport in silico-history, hype, hope. Curr. Top. Med. Chem. 3: 1193-1203
10. Davis, S. S. (1986) Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gammascintigraphy. S.T.P Pharma. 2: 1015-1022
11. Dressmann, J. B., Amidon, G. L., Fleisher, D. (1985) Absorption potential: estimating the fraction absorbed for orally administered drugs. J. Pharm. Sci. 74: 588-589
12. Dressmann, J. B., Amidon, G. L., Reppas, C., Shah, V. P. (1998) Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15: 11-22
13. Fagerholm, U., Bjornsson, M. A. (2005) Clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donating donator (CINOD) AZD3582. J. Pharm. Pharmacol. 57: 1539-1554
14. Fagerholm, U., Johansson, M., Lennernäs, H. (1996) Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13: 1336-1342
15. FDA (2000) Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
16. Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R. Reppas, C., Dressmann, J. B. (1998) Evaluation of various dissolution media for predicting in vivo performance of Class I and II drugs. Pharm. Res. 15: 698-705
17. Grass, G. M., Sinko, P. J. (2002) Physiologically-based pharmacokinetic simulation modeling. Adv. Drug Del. Rev. 54: 433-451
18. Irvine, J. D., Takahashi, L., Lackhart, K., Cheong, J., Tolan, J. W., Selick, H. E., Grove, J. R. (1999) MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88: 29-33
19. Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Junginger, H. E., Stavchansky, S. A., Midha, K. K., Shah, V. P., Amidon, G. L. (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharmaceut. 1: 85-96
20. Kataoka, M., Masaoka, Y., Yamazaki, Y., Sakane, T., Sezaki, H., Yamashita, S. (2003) In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. Pharm. Res. 20: 1674-1680
21. Klopman, G., Stefan, L. R., Saiakhov, R. D. (2002) ADME evaluation. 2. A computer model for the prediction of intestinal absorption in humans. Eur. J. Pharm. Sci. 17: 253-263
22. Kortejärvi, H., Mikkola, J., Bäckman, M., Antila, S., Marvola, M. (2002) Development of level A, B, C in vitro-in vivo correlations for modified-release levosimendan capsules. Int. J. Pharm. 241: 87-95
23. Kortejärvi, H., Urtti, A., Yliperttula, M. (2007) Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur. J. Pharm. Sci. 30: 155-166
24. Lennernäs, H., Abrahamsson, B. (2005) The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57: 273-285
25. Lennernäs, H., Palm, K., Fagerholm, U., Artursson, P. (1996) Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharmaceut. 127: 103-107
26. Liang, E., Proudfoot, J., Yazdanian, M. (2000) Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogues in Caco-2 cell monolayers. Pharm. Res. 17: 1168-1174
27. Lindahl, A., Ungell, A.-L., Knutson, L., Lennernäs, H. (1997) Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14: 497-502
28. Matsson, P., Bergström, C. A. S., Nagahara, N., Tavelin, S., Norinder, U., Artursson, P. (2005) Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48: 604-613
29. Parrott, N., Lavé, T. (2002) Prediction of intestinal absorption: comparative assessment of GastroPlus™ and IDEA™. Eur. J. Pharm. Sci. 17: 51-61
30. Pérez, M. A. C., Snaz, M. B., Torres, L. R., Ávalos, R. G., González, M. P., Díaz, H. G. (2004) A topological sub-structural approach for predicting human intestinal absorption. Eur. J. Med. Chem. 39: 905-916
31. rd world conference on drug absorption, transport and delivery. Barcelona, Spain.
32. Rowland, M., Tozer, T. N. (1995) In: Rowland, M., Tozer, T. N. (eds) Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, Baltimore, MD
33. Salphati, L., Childers, K., Pan, L., Tsutsui, K., Takahashi, L. (2001) Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J. Pharm. Pharmacol. 53: 1007-1013
34. Sun, D., Yu, L. X., Hussain, M. A., Wall, D. A., Smith, R. L., Amidon, G. L. (2004) In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Disc. Develop. 7: 75-85
35. Tavelin, S., Taipalensuu, J., Söderberg, L., Morrison, R., Chong, S., Artursson, P. (2003a) Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res. 20: 397-405
36. Tavelin, S., Taipalensuu, J., Hallböök, F., Vellonen, K.-S., Moore, V., Artursson, P. (2003b) An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharm. Res. 20: 373-381
37. US Pharmacist website. http://www.uspharmacist.com/NewLook/CE/ bioavail/lesson.htm
38. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., Dressman, J. B. (2004) A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47: 4022-4031
39. Wu, C.-Y., Benet, L. (2005) Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22: 11-23
40. Yalkowsky, S. H., Johnson, J. L. H., Sanghvi, T., Machatha, S. G. (2006) A 'rule of unity' for human intestinal absorption. Pharm. Res. 23: 2475-2481
41. Yazdanian, M., Glynn, S. L., Wright, J. L., Hawi, A. (1998) Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 15: 1490-1494
42. Yazdanian, M., Briggs, K., Jankovsky, C., Hawi, A. (2004) The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm. Res. 21: 293-299
43. Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Dhah, V. P., Lesko, L. J., Chen, M.-L., Lee, V. H. L., Hussain, A. S. (2002) Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19: 921-925
44. Zhao, Y. H., Abraham, M. H., Le, J., Hersey, A., Luscombe, C. N., Beck, G., Sherborne, B., Cooper, I. (2003) Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur. J. Med. Chem. 38: 233-243